Halberd Partnership Receives Contract from Defense Atomics Corporation to Treat Brain Injury and PTSD Page 1

Financial support and important additional tool to combat PTSD and TBI

JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) — Halberd Corporation (OTC PINK: HALB) is pleased to announce a major contract award commitment in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc. Defense Atomics Corporation has agreed to collaborate with the Halberd/Athena teams to fund important cutting-edge research, including the FDA's upcoming IND study utilizing Halberd's LDX technology and Athena Corporation's WatchDawg monitoring technology.

Defense Atomics Corporation has agreed to apply its proprietary CRISPR/nanotechnology stem cell treatment for PTSD/TBI to at least 10 paid veterans in a government pilot study of this cutting-edge protocol. Based on Defense Atomics' success in applying the CRISPR method to patients overseas, this study is designed to demonstrate the benefits of this technology in conjunction with Halberd/Athena's LDX PTSD and TBI/brain injury protocol.